tiprankstipranks
Arbutus Biopharma Corporation (ABUS)
NASDAQ:ABUS
US Market
ABUS
Arbutus Biopharma
RESEARCH TOOLSreports
Want to see ABUS full AI Analyst Report?

Arbutus Biopharma (ABUS) Earnings Dates, Call Summary & Reports

1,278 Followers

Earnings Data

Report Date
Jul 30, 2026
After Close (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.02
Last Year’s EPS
0.01
Same Quarter Last Year
Analyst Consensus
―
Based on 0 Analysts Ratings

Earnings Call Summary

Q3 2024
Earnings Call Date:Nov 06, 2024|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with strong financial positioning and promising clinical trial data for HBV treatments. However, ongoing legal challenges and high operational cash burn present concerns.
Company Guidance
In the third quarter 2024 earnings call for Arbutus Biopharma, the company provided several key metrics and updates on their ongoing efforts to develop a functional cure for chronic hepatitis B (HBV). They reported having approximately $131 million in cash and investments, with a projected cash burn for 2024 between $63 million and $67 million, ensuring their financial runway extends into the fourth quarter of 2026. The company is advancing their RNAi therapeutic imdusiran through Phase IIa trials, IM-PROVE I and II, which have shown promising results, such as a 33% surface antigen loss in Cohort A1 and 67% in patients with baseline antigen levels below 1,000 IU/mL. Moreover, they are progressing with their AB-101 clinical trial, with evidence of dose-dependent receptor occupancy in Phase Ia/Ib, and anticipate reporting preliminary HBV patient data in the first half of next year. The litigation with Moderna and Pfizer/BioNTech is ongoing, with a trial date set for September 2025 and a Markman hearing on December 18, 2024.
Strong Financial Position
Arbutus ended Q3 2024 with $131 million in cash, sufficient to fund operations into Q4 2026. A $44 million net proceeds from common shares issuance offset $54.5 million in operational cash usage.
Promising Clinical Data for Hepatitis B Treatment
Imdusiran showed promising results in reducing surface antigen levels in HBV patients. In Cohort A1 of the IM-PROVE I trial, 33% of patients achieved surface antigen loss sustained at 24 weeks post-treatment, with 67% of those with baseline less than 1,000 IU/mL maintaining loss.
Upcoming Data Presentations
Upcoming presentations at the Liver Meeting 2024 and AASLD will showcase additional data from ongoing HBV trials, indicating continued progress and interest in Arbutus' research.

Arbutus Biopharma (ABUS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

ABUS Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jul 30, 2026
2026 (Q2)
-0.02 / -
0.01―――
May 13, 2026
2026 (Q1)
-0.03 / 0.87
-0.13769.23% (+1.00)――
Mar 23, 2026
2025 (Q4)
-0.04 / -0.01
-0.0785.71% (+0.06)――
Nov 13, 2025
2025 (Q3)
-0.03 / -0.04
-0.160.00% (+0.06)――
Aug 06, 2025
2025 (Q2)
-0.05 / 0.01
-0.11109.09% (+0.12)――
May 14, 2025
2025 (Q1)
-0.10 / -0.13
-0.1-30.00% (-0.03)――
Mar 27, 2025
2024 (Q4)
-0.08 / -0.07
-0.1241.67% (+0.05)――
Nov 06, 2024
2024 (Q3)
-0.09 / -0.10
-0.1216.67% (+0.02)―
Aug 01, 2024
2024 (Q2)
-0.10 / -0.11
-0.1-10.00% (>-0.01)―
May 02, 2024
2024 (Q1)
-0.11 / -0.10
-0.10.00% (0.00)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ABUS Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 13, 2026
$4.31$4.310.00%
Mar 23, 2026
$4.24$4.42+4.25%
Nov 13, 2025
$4.84$4.56-5.79%
Aug 06, 2025
$3.41$3.47+1.76%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Arbutus Biopharma Corporation (ABUS) report earnings?
Arbutus Biopharma Corporation (ABUS) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
    What is Arbutus Biopharma Corporation (ABUS) earnings time?
    Arbutus Biopharma Corporation (ABUS) earnings time is at Jul 30, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ABUS EPS forecast?
          ABUS EPS forecast for the fiscal quarter 2026 (Q2) is -0.02.